Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy - Summary - MDSpire

Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy

  • By

  • Danai Dima

  • Al-Ola Abdallah

  • James A. Davis

  • Hussein Awada

  • Utkarsh Goel

  • Aliya Rashid

  • Shaun DeJarnette

  • Faiz Anwer

  • Leyla Shune

  • Shahzad Raza

  • Zahra Mahmoudjafari

  • Louis Williams

  • Beth Faiman

  • Joseph P. McGuirk

  • Craig S. Sauter

  • Nausheen Ahmed

  • Jack Khouri

  • Hamza Hashmi

  • May 31, 2024

  • 0 min

Share

Objective:

To assess the outcomes of relapsed-refractory multiple myeloma patients with active extraosseous extramedullary disease (EMD) defined as bone-independent tumors detected within 30 days of CAR T infusion, treated with CAR T-cell therapy.

Key Findings:
  • EMD is associated with adverse outcomes in RRMM patients receiving CAR T-cell therapy.
  • The study included 152 patients, with 71% receiving ide-cel and 29% receiving cilta-cel.
  • Presence of EMD predicts early progression after CAR T-cell therapy.
Interpretation:

The presence of extraosseous extramedullary disease significantly impacts the efficacy of CAR T-cell therapy in relapsed-refractory multiple myeloma patients, indicating a need for tailored treatment approaches that consider EMD's adverse effects.

Limitations:
  • Retrospective nature may introduce bias, particularly in patient selection and data completeness, which could affect the reliability of outcomes.
Conclusion:

The study highlights the need for further research on treatment strategies for RRMM patients with EMD, particularly focusing on the development of targeted therapies to improve outcomes following CAR T-cell therapy.

Original Source(s)

Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy

  • by Danai Dima, Al-Ola Abdallah, James A. Davis, Hussein Awada, Utkarsh Goel, Aliya Rashid, Shaun DeJarnette, Faiz Anwer, Leyla Shune, Shahzad Raza, Zahra Mahmoudjafari, Louis Williams, Beth Faiman, Joseph P. McGuirk, Craig S. Sauter, Nausheen Ahmed, Jack Khouri, Hamza Hashmi

  • May 31, 2024

Related Content

Prognostic nutritional index, but not NLR or PLR, is linked to survival in multiple myeloma

Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis

CRISPR Enables In Vivo CAR T Cell Production

In vivo gene editing strategy generates CAR T cells directly inside the body – sidestepping costly manufacturing

  • March 30, 2026

  • 2 min